Additional focus on lifestyle management, self-management education and support emphasized
Findings based on data reweighted to reflect the adult population with diabetes in the US.
Insulin products chart with pharmacokinetic properties.
Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria.
Despite having been withdrawn, albiglutide is superior to placebo for reducing cardiovascular events
Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.
New study reveals a type 2 diabetes incidence rate of 17.81 cases per 1000 person-years, a rate much higher than in the general population.
Treatment options for obesity including strength, form, and dosing details.
Antidiabetic agents for the treatment of diabetes including maintenance and max doses chart.
Measurement of plasma copeptin better than water-deprivation test in patients with hypotonic polyuria.
Associated with increased risk of myocardial infarction, all-cause mortality, severe hypoglycemia.
Changes will describe hypoglycemic coma and clarify and identify mental health side effects.
Increased risk seen for women but not men; slightly attenuated after adjustment for mediating factors.
Eversense CGM, which has fully implantable sensor to detect glucose, approved for adults with diabetes.
Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.
Better glycemic control than conventional subcutaneous insulin therapy in patients with T2DM.
In subgroup analyses, reduced incidence of cancer seen in participants aged younger than 65 years.
Target HbA1c 7 to 8 for most patients with T2DM; deintensification of tx with HbA1c 6.5
Independently linked to major cardiovascular events, especially heart failure hospitalizations.
Medication reconciliation linked to lower risk of combined ER visits, hospitalization over 6 months.
In a South Korean study, nearly 60% of elderly patients with type 2 diabetes had chronic kidney disease at baseline.
Increased risk of subsequent diabetes independent of traditional diabetes risk factors.
New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.
Within 6 months of elevated HbA1c, rate of initiation 63%, rate of intensification 82%.
Type 2 diabetes is among the leading causes of end-stage renal disease (ESRD), but the estimated cumulative risk of ESRD at 20 years after diagnosis of type 2 diabetes is less than 1%.
Insulin Pen Devices comparison chart for patients with diabetes mellitus.
Decrease in length of stay and mortality, but increase in mean hospital charges during study period.
Frequency of primary outcome was 27.6 and 23.4% in glyburide and insulin groups, respectively.
Major adverse CV and cerebrovascular events with noncardiac sx have also increased in DM patients
Aortic distensibility independently linked to concentric left ventricular remodeling
Renal and Urology News Articles
- Genetic Differences in Prostate Cancer Pinpointed in Black Men
- Clinical Gout-Related Benefits Not Seen With Lesinurad Combo Tx
- High Variability in Metabolic Measures May Up Mortality
- Sitagliptin Better for Glycemic Control in T2D With Renal Impairment
- Ultrasound Can Reveal Renal Medulla Urate Deposits in Tophaceous Gout
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)